Format

Send to

Choose Destination
Liver Int. 2018 Mar;38(3):443-450. doi: 10.1111/liv.13534. Epub 2017 Oct 22.

Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.

Author information

1
Department of Hepatology, Hôpital Beaujon, APHP, INSERM CRI, UMR1149, University Paris-Diderot, Clichy, France.
2
Campus Stuivenberg, Antwerp, Belgium.
3
Monash Health and Monash University, Clayton, Vic., Australia.
4
Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany.
5
Johns Hopkins University, Baltimore, MD, USA.
6
Queen Mary University London, London, UK.
7
Gilead Sciences Inc., Foster City, CA, USA.
8
Auckland Clinical Studies Ltd, Auckland, New Zealand.
9
Toronto Centre for Liver Disease, Toronto, ON, Canada.
10
Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy.

Abstract

BACKGROUND & AIMS:

Patients with chronic hepatitis C virus infection and advanced fibrosis (Metavir F3) or cirrhosis (Metavir F4) have been identified as a priority group for immediate treatment. We evaluated the safety and efficacy of sofosbuvir-velpatasvir in patients with hepatitis C virus genotype 1-6 infection and compensated cirrhosis or advanced fibrosis.

METHODS:

This retrospective analysis included 501 patients with compensated cirrhosis or advanced fibrosis (F3/F4), as defined by >0.59 on Fibrotest, >9.5 kPa on Fibroscan, or F3/F4 (Metavir) or F4 (Ishak) on liver biopsy. Patients received sofosbuvir-velpatasvir for 12 weeks. Sustained virological response 12 weeks after treatment was determined.

RESULTS:

Forty-four per cent of patients had cirrhosis. Sustained virological response 12 weeks after treatment was achieved by 98% of patients (490/501; 95% confidence interval, 96-99). Sustained virological response 12 weeks after treatment rates were 100% for hepatitis C virus genotypes 2 (85/85), 4 (60/60), 5 (13/13), and 6 (20/20). Sustained virological response 12 weeks after treatment rates were 98% (167/170) in hepatitis C virus genotype 1 patients and 95% (145/153) in hepatitis C virus genotype 3 patients. Among patients with cirrhosis 96% (212/220) achieved sustained virological response 12 weeks after treatment, vs 99% (278/281) for those with advanced fibrosis. Sustained virological response 12 weeks after treatment was 98% (306/311) for treatment-naïve patients and 97% (184/190) for treatment-experienced patients. No patients discontinued treatment due to adverse events. Eight patients reported nine serious adverse events; none was considered related to study procedures or drugs.

CONCLUSIONS:

Sofosbuvir plus velpatasvir is highly effective and safe for treating patients with hepatitis C virus genotypes 1, 2, 3, 4, 5 or 6 and advanced fibrosis or compensated cirrhosis.

KEYWORDS:

NS5A inhibitor; antiviral agents; direct-acting antivirals; polymerase inhibitor

PMID:
28756625
DOI:
10.1111/liv.13534
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center